Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Follow us on Google+Follow us on TwitterFind us on LinkedInFind Us on FacebookSubscribe to our RSS FeedsSubscribe to our YouTube ChannelFind us on RebelMouse

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Date    |    Business Directory
All Press Releases for January 08, 2014 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version   



A US Patent on ITE for Cancer Intervention and Eradication Issued to AhR Pharmaceuticals, Inc.

AhR Pharmaceuticals announces the issuance of its first own patent by USPTO (United States Patent and Trademark Office).
 
x-small text small text medium text large text

  • <strong>AhR Pharma Logo</strong>
  • <strong>ITE Space Filling Model</strong>

"We are glad to see the recognition by the USPTO of our invention to the benefit of patients around the world," said Dr. Jason Song, the Chief Scientific Officer of AhR Pharmaceuticals.

    MADISON, WI, January 08, 2014 /24-7PressRelease/ -- The first patent of AhR Pharmaceuticals' has been issued by the United States Patent and Trademark Office (USPTO). The issued US patent covers the use of ITE and its structural analogs for cancer intervention and possible eradication. The international equivalents of the issued US patent are currently under prosecution in intellectual property offices of countries around the globe.

ITE is an endogenous ligand or natural hormone for the aryl hydrocarbon receptor. Once binding to the receptor, ITE activates and drives the hormone-receptor complex in mediating a series of important biological and pharmacological processes in the body. Evidences collected by scientists from AhR Pharmaceuticals and a global research community, as well, have demonstrated ITE's potentials in treating cancer, obesity, and disorders related to imbalanced actions of immune systems.

"We are glad to see the recognition by the USPTO of our innovation and invention to the benefit of patients around the world," said Dr. Jiasheng (Jason) Song, the Chief Scientific Officer of AhR Pharmaceuticals. "We have been prosecuting pending patents around the world and will continue the filing of patent applications from our important inventions to protect our intellectual property and build values for our investors," continued Dr. Song. "More importantly, by doing all of these, it will ultimately enable us to do tremendously good things to benefit our patients around the globe."

The patent (US 8,604,067 B2) is entitled "ITE for Cancer Intervention and Eradication". The inventor of the patent is Dr. Jiasheng (Jason) Song, the major inventor of ITE technologies and Chief Scientific Officer of AhR Pharmaceuticals (the assignee and owner of the issued US patent). To obtain the full text of the issued US patent, please follow the link: http://www.ahrpharma.com/AhR-Issued-US-8,604,067-ITE-Cancer-Interven-Eradicat.pdf

AhR Pharmaceuticals, Inc., with licensed ITE technologies as its foundational intellectual property from Wisconsin Alumni Research Foundation (WARF, the intellectual property manager of University of Wisconsin-Madison, a world-renowned research university), is devoted to the development of the natural hormone ITE into an efficacious and sustainable but low side-effect therapeutic agent in intervention of cancer (with a possibility of eradication), obesity, and disorders due to imbalanced actions of immune systems. For more information on AhR Pharmaceuticals, Inc., its technologies, and research activities, please visit www.ahrpharma.com.



---
Press release service and press release distribution provided by http://www.24-7pressrelease.com


# # #



Contact Information:
Jason Song
AhR Pharmaceuticals, Inc.

Madison, WI
USA
Voice: 1-608-692-4791
E-Mail: Email us Here
Website: Visit Our Website
Follow Us:
 Follow Us on Google+ Follow Us on LinkedIn Follow Us on Twitter
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7PressRelease. We are unable to assist you with any information regarding this release. 24-7PressRelease disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.